P2RX3 and Crohn disease: Newly developed compounds such as the P2Y2 agonist denufusol (cystic fibrosis) and the P2X7 antagonist AZD 9056 (Crohn’s disease) demonstrate the therapeutic potential of agonists and antagonists of purinergic receptors in various human diseases [78].